Restenoses following successful coronary angioplasty occur in about 30 to 35% and are the most important limitative factor of this method. The etiology of restenosis is multifactorial. A beneficial effect in reducing restenosis could not be demonstrated for any drug in the clinical stage. First results with the administration of n-3-fatty acids revealed a favourable influence on recurrence. Further on, the value of newer interventional methods on restenosis rate is also uncertain. Thus, the problem of restenosis remains unresolved.